Arcturus Therapeutics Newsroom

Unveiling 3 Analyst Insights On Arcturus Therapeutics

BenzingaOct 2 05:00

H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63

Futu NewsOct 2 00:32 · Ratings

Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.

Dow JonesOct 2 00:22 · Ratings

Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58

Futu NewsOct 1 17:31 · Ratings

Express News | Self-Amplifying Mrna Covid-19 Vaccine Demonstrates Superior Immune Response Compared With Mrna Vaccine at 12 Months Post-Vaccination

BreakingsSep 30 20:00

Arcturus Therapeutics, CSL's Updated Covid-19 Vaccine Approved in Japan

MT NewswiresSep 13 20:48

Express News | Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-Amplifying Mrna Covid-19 Vaccine for Protection Against Jn.1 Strain, to Be Distributed in Japan by Meiji Seika Pharma

BreakingsSep 13 20:00

Leerink Partners Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating

Leerink Partners analyst Lili (Aurélie) Nsongo maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 0.0% and a total average

Futu NewsSep 13 14:32 · Ratings

Arcturus Therapeutics: Strong Buy Rating on Promising Vaccine Distribution and Advancements in Rare Disease Treatments

TipRanksSep 13 13:57

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics

Analyst UpgradesSep 10 00:54

While Shareholders of Arcturus Therapeutics Holdings (NASDAQ:ARCT) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate

Simply Wall StSep 9 22:01

Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers

Yahoo FinanceSep 9 04:51

William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating

William Blair analyst Myles Minter maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.5% and a total average return of 8.5%

Futu NewsSep 5 00:32 · Ratings

Buy Rating Affirmed: Arcturus Therapeutics' Promising Cystic Fibrosis Program Progress

TipRanksSep 4 19:05 · Ratings

Express News | Arcturus Therapeutics : To Initiate Phase 2 Study for Arct-032

BreakingsSep 3 20:40

Express News | Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for Arct-032, an Investigational Inhaled Mrna Therapeutic to Treat Cystic Fibrosis

BreakingsSep 3 20:30

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled MRNA Therapeutic to Treat Cystic Fibrosis

Yahoo FinanceSep 3 20:30

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

newsfilter.ioAug 28 05:00

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $72

CCORF analyst Whitney Ijem maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating, and maintains the target price at $72.According to TipRanks data, the analyst has a success rate of 52.0% and

Futu NewsAug 27 19:31 · Ratings

Arcturus Therapeutics: A Strong Buy on Promising Vaccine Developments and Strategic Collaborations

TipRanksAug 27 18:45